Influence of fibrate treatment on malondialdehyde-modified LDL concentration

Clinica Chimica Acta

Volumn 339, Issue 1-2, 2004, Pages 97-103

  Kondo, Akira ^a,b   Morita, Hiroshi ^b   Nakamura, Hirotoshi ^b   Kotani, Kazuo ^a   Kobori, Kiichiro ^a   Ito, Sachiko ^a   Manabe, Mitsuhisa ^a   Saito, Kazunori ^a   Kanno, Takashi ^b   Maekawa, Masato ^a  

^a DAIICHI PURE CHEMICALS CO LTD   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoprotein B; Bezafibrate; Diabetes mellitus; Hypertriglyceridemia; Oxidation; Small dense LDL

Indexed keywords

APOLIPOPROTEIN B; FIBRIC ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEX DIFFERENCE;

EID: 10744220035     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.09.005     Document Type: Article

References (24)

1. Solberg L.A., Strong J.P. Risk factors and atherosclerotic lesions: a review of autopsy studies. Arteriosclerosis. 3:1983;187-198.
2. Grundy S.M. Cholesterol and coronary heart disease. A new era. JAMA. 256:1986;2849-2858.
3. Fogelman A.M., Shechter I., Seager J., Hokom M., Child J.S., Edwaeds P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl. Acad. Sci. U.S.A. 77:1980;2214-2218.
4. Shechter I., Fogelman A.M., Haberland M.E., Seager J., Hokom M., Edwards P.A. The metabolism of native and malondialdehyde-altered low density lipoproteins by human monocyte-macrophages. J. Lipid Res. 22:1981;63-71.
5. Haberland M.E., Fong D., Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241:1988;215-218.
6. Holvoet P., Perez G., Zhao Z., Brouwers E., Bernar H., Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin. Invest. 95:1995;2611-2619.
7. Requena J.R., Fu M.X., Ahmed M.U.et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem. J. 322:1997;317-325.
8. Kondo A., Muranaka Y., Ohta I.et al. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin. Chem. 47:2001;893-900.
9. Frick M.H., Elo O., Haapa K.et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged with dyslipidemia. N. Engl. J. Med. 317:1987;1237-1245.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
11. Brunzell J.D., Bierman E.L. Chylomicronemia syndrome: interaction of genetic and acquired hypertriglyceridemia. Med. Clin. North. Am. 66:1982;455-468.
12. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygoted. Trans. Assoc. Am. Physicians. 96:1983;1-9.
13. Kondo A., Manabe M., Saito K., Maekawa M., Kanno T. Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes. J. Atheroscler. Thromb. 9:2002;280-287.
14. Diabetes Mellitus: Report of a WHO Study Group. 1985;World Health Organization, Geneva. Tech. Rep. Ser., No. 727.
15. Williams P.T., Krauss R.M., Nichols A.V., Vranizan K.M., Wood P.D.S. Identifying the predominant peak diameter of high-density and low-density lipoproteins by electrophoresis. J. Lipid Res. 31:1990;1131-1139.
16. Tilly-Kiesi M., Tikkanen M.J. Low density lipoprotein density and composition in hypercholesterolemic men treated with HMG CoA reductase inhibitors and gemfibrozil. J. Intern. Med. 229:1991;427-434.
17. Yuan J., Tsai M.Y., Hunninghake D.B. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis. 110:1994;1-11.
18. Homma Y., Ozawa H., Kobayashi T.et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis. 106:1994;191-201.
19. Ruotolo G., Ericsson C-G., Tettamanti C.et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J. Am. Coll. Cardiol. 32:1998;1648-1656.
20. Galeano N.F., Milne R., Marcel Y.L.et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J. Biol. Chem. 269:1994;511-519.
21. De Graaf J., Hak-Lemmers H.L., Hectors M.P., Demacker P.N., Hendriks J.C., Stalenhoef A.F. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11:1991;298-306.
22. Chait A., Brazg R.L., Tribble D.L., Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype pattern B. Am. J. Med. 94:1993;350-356.
23. Kotani K., Maekawa M., Kanno T., Kondo A., Toda N., Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim. Biophys. Acta. 1215:1994;121-125.
24. Hunt J.V., Smith C.C.T., Wolff S.P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes. 39:1990;1420-1424.